Clearside Biomedical, Inc. (CLSD)
NASDAQ: CLSD · Real-Time Price · USD
1.080
+0.060 (5.88%)
Nov 22, 2024, 4:00 PM EST - Market closed
Clearside Biomedical Revenue
Clearside Biomedical had revenue of $1.04M in the quarter ending September 30, 2024, with 20.84% growth. This brings the company's revenue in the last twelve months to $7.70M, up 248.39% year-over-year. In the year 2023, Clearside Biomedical had annual revenue of $8.23M with 519.89% growth.
Revenue (ttm)
$7.70M
Revenue Growth
+248.39%
P/S Ratio
9.88
Revenue / Employee
$256,767
Employees
30
Market Cap
81.91M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 8.23M | 6.90M | 519.89% |
Dec 31, 2022 | 1.33M | -28.25M | -95.51% |
Dec 31, 2021 | 29.58M | 21.68M | 274.65% |
Dec 31, 2020 | 7.89M | 5.72M | 263.28% |
Dec 31, 2019 | 2.17M | 2.14M | 7,143.33% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
P3 Health Partners | 1.48B |
CASI Pharmaceuticals | 22.06M |
CervoMed | 10.07M |
Armata Pharmaceuticals | 5.47M |
I-Mab | 3.31M |
CLSD News
- 11 days ago - Clearside Biomedical, Inc. (CLSD) Q3 2024 Earnings Conference Call Transcript - Seeking Alpha
- 16 days ago - Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema - GlobeNewsWire
- 17 days ago - Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference - GlobeNewsWire
- 19 days ago - Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors - GlobeNewsWire
- 23 days ago - Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024 - GlobeNewsWire
- 4 weeks ago - Clearside Biomedical's Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting - GlobeNewsWire
- 6 weeks ago - Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes - GlobeNewsWire
- 3 months ago - Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD - GlobeNewsWire